%20--%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%20100.6%2073.7'%20style='enable-background:new%200%200%20100.6%2073.7;'%20xml:space='preserve'%3e%3cstyle%20type='text/css'%3e%20.st0{fill:%23AF001E;}%20.st1{fill:%23FFFFFF;}%20%3c/style%3e%3cg%3e%3crect%20class='st0'%20width='100.6'%20height='73.7'/%3e%3cpath%20class='st1'%20d='M25.2,36.3l-0.5,2.3c-0.2,0.7-0.2,1-0.2,1.2c0,0.5,0.2,1,0.5,1.6L31.5,53c0.5,0.9,1,1.3,2.3,1.3h5.9%20c0.8,0,1.7-0.5,0.8-1.8l-7.9-13.1c2.7-1.7,5.6-4.1,5.6-9.3c0-6.8-3.8-10.6-12.2-10.6H13.9c-1.1,0-1.4,0.4-1.4,1.5v32%20c0,1.1,0.3,1.5,1.4,1.5h5c1.1,0,1.4-0.4,1.4-1.5V26h5.2c3.3,0,4.8,1.2,4.8,4.2c0,2.8-1.2,3.6-2.5,4.2C26.3,35,25.7,34.3,25.2,36.3z%20'/%3e%3cpath%20class='st1'%20d='M45.9,48.8L45.3,53c-0.1,0.8,0.3,1.1,1,1.2c1.6,0.2,5.5,0.5,9.4,0.5c8.6,0,14.9-2.8,14.9-10.9%20c0-4.7-2.1-8.3-9.2-10.1l-4-1c-2.7-0.7-4-1.6-4-3.6c0-2.8,2.6-3.4,5.1-3.4c3.4,0,6.8,0.3,8.1,0.4c1.4,0.1,1.8-0.1,2-1.2l0.7-4.1%20c0.1-0.8-0.3-1.1-1-1.2c-1.6-0.2-5-0.5-9.4-0.5c-9,0-13.3,3.9-13.3,10.1c0,5.6,3,8.9,8.3,10.3l4,1c3.3,0.9,4.7,1.8,4.7,3.9%20c0,3-2.1,3.6-7.1,3.6c-2.3,0-6.2-0.3-7.6-0.4C46.5,47.4,46.1,47.6,45.9,48.8z'/%3e%3cpath%20class='st1'%20d='M79.4,52.9c0,1.1,0.3,1.5,1.4,1.5h5c1.1,0,1.4-0.4,1.4-1.5v-32c0-1.1-0.3-1.5-1.4-1.5h-5%20c-1.1,0-1.4,0.4-1.4,1.5V52.9z'/%3e%3c/g%3e%3c/svg%3e)
Un articolo pubblicato sulla rivista scientifica Cell presenta lo studio preclinico svolto nell’ambito dello sviluppo di un promettente anticorpo, chiamato MEDI8852, quale possibile trattamento terapeutico di molti sottotipi di influenza A - l’agente eziologico delle infezioni stagionali - e, potenzialmente, di nuove pandemie.
Lo studio descrive il meccanismo d’azione di MEDI8852 che, date le sue peculiari proprietà di legame, potrebbe aprire la strada al futuro sviluppo di un vaccino universale contro tutti i virus influenzali di tipo A, evitando così che nuovi vaccini debbano essere prodotti ogni anno per proteggere dai nuovi virus circolanti.
Il lavoro è il risultato dalla collaborazione internazionale tra i ricercatori dell’azienda MedImmune, il ramo di ricerca e sviluppo della società AstraZeneca, Humabs BioMed, l’Istituto di Ricerca in Biomedicina (IRB, Università della Svizzera italiana) e l’istituto Francis Crick di Londra.
Swing
%20--%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%20138.2%2048'%20style='enable-background:new%200%200%20138.2%2048;'%20xml:space='preserve'%3e%3cstyle%20type='text/css'%3e%20.st0{fill-rule:evenodd;clip-rule:evenodd;fill:%23AF001E;}%20.st1{fill-rule:evenodd;clip-rule:evenodd;fill:%23FFFFFF;}%20%3c/style%3e%3cpath%20class='st0'%20d='M0,48h138V0H0V48z'/%3e%3cpath%20class='st1'%20d='M9.3,31.7l-0.4,2.7C8.8,35,9,35.2,9.5,35.3c2,0.2,4,0.3,6.1,0.3c5.6,0,9.7-1.8,9.7-7.1c0-3.1-1.3-5.4-6-6.6%20l-2.6-0.7c-1.8-0.5-2.6-1-2.6-2.3c0-1.9,1.7-2.2,3.3-2.2c2.2,0,4.4,0.2,5.3,0.2c0.9,0.1,1.2,0,1.3-0.8l0.4-2.6c0-0.1,0-0.2,0-0.3%20c0-0.1-0.1-0.2-0.1-0.3s-0.1-0.1-0.2-0.2c-0.1,0-0.2-0.1-0.3-0.1c-2-0.2-4.1-0.3-6.1-0.3C11.8,12.4,9,14.9,9,19c0,3.6,2,5.8,5.4,6.7%20l2.6,0.7c2.1,0.6,3,1.2,3,2.5c0,2-1.3,2.3-4.6,2.3c-1.5,0-4-0.2-4.9-0.3C9.6,30.9,9.4,31,9.3,31.7'/%3e%3cpath%20class='st1'%20d='M36.4,23.6l-0.3,1.5C36,25.4,36,25.6,36,25.9c0,0.4,0.1,0.8,0.4,1.1l4.2,7.6c0.1,0.3,0.3,0.5,0.6,0.7%20c0.3,0.2,0.6,0.2,0.9,0.2h3.8c0.5,0,1.1-0.3,0.5-1.2l-5.1-8.6c1.7-1.1,3.6-2.6,3.6-6.1c0-4.4-2.5-6.9-7.9-6.9h-7.8%20c-0.7,0-0.9,0.2-0.9,1v20.8c0,0.7,0.2,1,0.9,1h3.2c0.7,0,0.9-0.2,0.9-1V16.8h3.3c2.1,0,3.1,0.8,3.1,2.8c0.1,0.6,0,1.2-0.3,1.6%20c-0.3,0.5-0.7,0.9-1.3,1.1C37.1,22.7,36.8,22.3,36.4,23.6z'/%3e%3cpath%20class='st1'%20d='M66.1,34V22.7c0-0.7-0.2-1-0.9-1h-5.8c-0.7,0-0.9,0.2-0.9,1v2.5c0,0.7,0.2,0.9,0.9,0.9h1.7v5%20c-0.6,0.1-1.1,0.1-1.7,0.1c-4.8,0-6-3.1-6-7.4c0-5.4,2-6.8,6.5-6.8c1.3,0,3.1,0.1,4.1,0.2c1,0.1,1.2,0,1.3-0.8l0.4-2.5%20c0.1-0.7,0-1-0.8-1.1c-1.8-0.2-3.6-0.3-5.4-0.2c-8.2,0-11.6,4.3-11.6,11.3s2.7,11.9,11.3,11.9c2,0.1,4,0,6-0.4%20C65.9,35.2,66.2,34.9,66.1,34'/%3e%3cpath%20class='st1'%20d='M74.9,31.7l-0.4,2.7c-0.1,0.5,0.2,0.7,0.6,0.8c2,0.2,4,0.3,6.1,0.3c5.6,0,9.7-1.8,9.7-7.1c0-3.1-1.3-5.4-6-6.6%20l-2.6-0.7c-1.8-0.5-2.6-1-2.6-2.3c0-1.9,1.7-2.2,3.3-2.2c2.2,0,4.4,0.2,5.3,0.2c0.9,0.1,1.2,0,1.3-0.8l0.4-2.6c0-0.1,0-0.2,0-0.3%20c0-0.1-0.1-0.2-0.1-0.3s-0.1-0.1-0.2-0.2c-0.1,0-0.2-0.1-0.3-0.1c-2-0.2-4.1-0.3-6.1-0.3c-5.8,0-8.6,2.6-8.6,6.6%20c0,3.6,2,5.8,5.4,6.7l2.6,0.7c2.1,0.6,3,1.2,3,2.6c0,2-1.3,2.3-4.6,2.3c-1.5,0-4-0.2-4.9-0.3C75.3,30.8,75,30.9,74.9,31.7'/%3e%3cpath%20class='st1'%20d='M93.1,31.7l-0.4,2.7c-0.1,0.5,0.2,0.7,0.6,0.8c2,0.2,4,0.3,6.1,0.3c5.6,0,9.7-1.8,9.7-7.1c0-3.1-1.3-5.4-6-6.6%20l-2.6-0.7c-1.8-0.5-2.6-1-2.6-2.3c0-1.9,1.7-2.2,3.3-2.2c2.2,0,4.4,0.2,5.3,0.2c0.9,0.1,1.2,0,1.3-0.8l0.4-2.6c0-0.1,0-0.2,0-0.3%20c0-0.1-0.1-0.2-0.1-0.3c-0.1-0.1-0.1-0.1-0.2-0.2c-0.1,0-0.2-0.1-0.3-0.1c-2-0.2-4.1-0.3-6.1-0.3c-5.8,0-8.6,2.6-8.6,6.6%20c0,3.6,2,5.8,5.4,6.7l2.6,0.7c2.1,0.6,3,1.2,3,2.6c0,2-1.3,2.3-4.6,2.3c-1.5,0-4-0.2-4.9-0.3S93.1,30.9,93.1,31.7'/%3e%3cpath%20class='st1'%20d='M120.2,23.6l-0.3,1.5c-0.1,0.3-0.1,0.5-0.1,0.8c0,0.4,0.1,0.8,0.3,1.1l4.2,7.6c0.1,0.3,0.3,0.5,0.6,0.7%20c0.3,0.2,0.6,0.2,0.9,0.2h3.8c0.5,0,1.1-0.3,0.5-1.2l-5.1-8.6c1.7-1.1,3.7-2.7,3.7-6.1c0-4.4-2.5-6.9-7.9-6.9H113%20c-0.7,0-0.9,0.2-0.9,1v20.8c0,0.7,0.2,1,0.9,1h3.2c0.7,0,0.9-0.2,0.9-1V16.8h3.3c2.1,0,3.1,0.8,3.1,2.8c0.1,0.6,0,1.2-0.3,1.6%20c-0.3,0.5-0.7,0.9-1.3,1.1C120.9,22.7,120.6,22.3,120.2,23.6'/%3e%3c/svg%3e)